Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United Kingdom-Reference-Cited by-同舟云学术

Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United Kingdom

Published:2020-12-01 Issue:12 Volume:19 Page:1167-1175
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Mathijssen D. A. R.¹,Heisen M.¹^ORCID,Clark-Wright J. F.²,Wolfson L. J.³^ORCID,Lu X.³,Carrol S.²,van Dijk B.C.P.¹,Klijn S. L.¹,Alemayehu B.³

Affiliation:

1. Pharmerit - an OPEN health company, Rotterdam, The Netherlands

2. Sanofi Pasteur UK & Ireland, Reading, United Kingdom

3. Merck & Co., Inc., Kenilworth, NJ, USA

Funder

Merck Sharp & Dohme Corp

Merck & Co., Inc., Kenilworth, NJ, USA

Sanofi Pasteur, Inc

Swiftwater, PA, USA

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2020.1873770

Reference26 articles.

1. World Health Organization (WHO). Immunization 2020 [cited 2020 Oct 08]. Available from: https://www.who.int/topics/immunization/en/

2. World Health Organization (WHO). Country profiles, data, and statistics on immunization 2020 [cited 2020 Oct 08] 2020]. Available from: https://www.who.int/immunization/monitoring_surveillance/en/

3. Inappropriately timed immunizations: types, causes, and their relationship to record keeping.

4. SHARPS INJURIES AMONGST HEALTHCARE WORKERS: REVIEW OF INCIDENCE, TRANSMISSIONS AND COSTS

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China;Human Vaccines & Immunotherapeutics;2024-04-15

2. Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines: a discrete-choice experiment;Current Medical Research and Opinion;2024-03-19

3. Estimating the Total Societal Cost of a Hexavalent Vaccine versus a Pentavalent Vaccine with Hepatitis B in South Korea;Vaccines;2023-05-15

4. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age;Human Vaccines & Immunotherapeutics;2022-08-10

5. Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization;Value in Health Regional Issues;2021-12